Chuck Schumer, US Senate Majority Leader

Covid-19 man­u­fac­tur­ing roundup: Ri­ton­avir pro­duc­tion to reach 100M dos­es an­nu­al­ly; Schumer calls for a boost to do­mes­tic vac­cine sup­ply

Amid the spike in pos­i­tive Covid-19 cas­es thanks to the Omi­cron vari­ant, As­cle­tis will ex­pand its pro­duc­tion of the oral tablet ri­ton­avir to pro­duce 100 mil­lion dos­es a year. And the com­pa­ny is ready to in­crease that num­ber if the mar­ket calls for that.

ASC10 tar­gets RNA de­pen­dent RNA poly­merase, while ASC11 tar­gets 3-chy­motrypsin-like pro­tease. As­cle­tis cur­rent­ly owns the on­ly au­tho­rized ri­ton­avir tablet in Chi­na, which was ap­proved in Sep­tem­ber. A low dose ri­ton­avir oral tablet (100mg) is a com­po­nent of Paxlovid, Pfiz­er’s drug that re­cent­ly land­ed a con­tract with the Bel­gian gov­ern­ment for 10,000 cours­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.